Best Pharma Stocks Based on Artificial Intelligence: Returns up to 35.67% in 1 Month

Pharma Stocks Forecast Package Name: Pharma Stocks
Recommended Positions: Long & Short
Forecast Length: 1 Month (11/13/2018 - 12/13/2018)
I Know First Average: 4.55% (Long) & 3.78% (Short)

Read The Full Forecast

Best Pharma Stocks

Healthcare Stocks Outlook Based on Stock Prediction Algorithm: Returns up to 29.51% in 1 Month

Healthcare Package Name: HealthCare Stocks
Recommended Positions: Short
Forecast Length: 1 Month (10/12/2018 - 11/12/2018)
I Know First Average: 16.65%

Read The Full Forecast

Healthcare Stocks Outlook

Machine Learning Trading Based on Stock Prediction Algorithm: Returns up to 19.99% in 1 Month

Package Name: Top 10 Stocks
Recommended Positions: Short
Forecast Length: 1 Month (09/23/2018 - 10/23/2018)
I Know First Average: 10.04%

Read The Full Forecast

Machine Learning Trading

Top Stock Research Based on Deep Learning: Returns up to 16.35% in 1 Month

Package Name: Top 10 Stocks
Recommended Positions: Short
Forecast Length: 1 Month (09/17/2018 - 10/17/2018)
I Know First Average: 5.90%

Read The Full Forecast

Top Stock Research

Top 10 Stocks to Short Based on Data Mining: Returns up to 20.36% in 14 Days

Package Name: Top 10 Stocks
Recommended Positions: Short
Forecast Length: 14 Days (09/26/2018 - 10/10/2018)
I Know First Average: 9.17%

Read The Full Forecast

Top 10 Blue Chip Stocks

Systematic Trading Based on AI: Returns up to 15.44% in 7 Days

Package Name: Top 10 Stocks
Recommended Positions: Short
Forecast Length: 7 Days (10/03/2018 - 10/10/2018)
I Know First Average: 8.41%

Read The Full Forecast

Systematic Trading

Winning HRTX Stock Forecast: Heron Therapeutics Gained 46.99% 3 Months After Strong Bullish Signal

“HTX-011 is the only long-acting local anesthetic to demonstrate significantly reduced postoperative pain and opioid use through 72 hours compared to bupivacaine solution, the standard-of-care local anesthetic for postoperative pain management, in Phase 3 studies. We look forward to working towards the submission of an NDA to the FDA for HTX-011 in the second half of 2018.”

– Barry D. Quart, Pharm.D., CEO of Heron Therapeutics.

(Source: smarteranalyst.com)

Just in three months from March 25th, 2018, Heron Therapeutics Inc (NYSE: HRTX) has gained 46.99%. The main reason for

Read More